Evidence map›Paper›PMID 33628550›Full record

ArticleCase reports in oncological medicine2020

Primary Malignant Melanoma of the Cervix: A Case Report and a Review of the Literature.

Michail Diakosavvas, Zacharias N Fasoulakis, Maria Kouroupi, Marianna Theodora, Lola Inagamova, Georgios Tsatsaris, Panagiotis Nikolaou, Konstantina Frangia-Tsivou, Alexandra Giatromanolaki, Emmanuel N Kontomanolis

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in oncological medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Michail DiakosavvasDepartment of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Greece.
Zacharias N FasoulakisDepartment of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Greece.ORCID https://orcid.org/0000-0003-0216-3420
Maria KouroupiDepartment of Pathology, Democritus University of Thrace, Greece.
Marianna TheodoraDepartment of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Greece.
Lola InagamovaDepartment of Obstetrics and Gynecology, National and Kapodistrian University of Athens, Greece.
Georgios TsatsarisDepartment of Obstetrics and Gynecology, Democritus University of Thrace, Greece.
Panagiotis NikolaouDepartment of Obstetrics and Gynecology, Democritus University of Thrace, Greece.
Konstantina Frangia-TsivouHISTOBIO Diagnosis, Athens, Greece.
Alexandra GiatromanolakiDepartment of Pathology, Democritus University of Thrace, Greece.
Emmanuel N KontomanolisDepartment of Obstetrics and Gynecology, Democritus University of Thrace, Greece.
Democritus University of Thrace · GRNational and Kapodistrian University of Athens · GRAthens Medical Center · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGynecologic melanomas are extremely rare malignancies, and primary malignant melanoma of the cervix (PMMC) is the rarest among them all, with less than 100 cases reported so far. Although some conditions have been correlated with the pathogenesis of this entity, no specific risk factor has been yet identified, with vaginal bleeding being the most common symptoms. The diagnosis is based on physical examination with speculum assessment and cytologic and histopathologic findings accompanied with immunohistochemical staining of lesion's biopsies.

conclusionsEarly diagnosis and subsequently early treatment are of high importance regarding patients' prognosis and survival. No standardized protocols or treatment guidelines specific for this rare cancer have been issued; thus, clinicians are called to assess each case individually. Current treatment options are based on surgical excision mostly with radical hysterectomy, but in advanced or recurrent state of the disease, other treatment modalities, such as chemotherapy, radiotherapy, and immunotherapy, can be employed. Prognosis for these patients is very poor, and survival rate remains extremely low, with the median OS reported being less than 2 years. Reporting and publishing of such cases are both of paramount importance for the better understanding of this uncommon cervical malignancy, and further biological and clinical investigations are required for more suitable and effective therapies to be determined. A new staging system, specific to PMMC, could be of great use for the better correlation of the disease's stage and prognosis of these patients.

Identifiers

PMID33628550
PMCPMC7898279
OpenAlexW3082551786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.